Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...
Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...
However, a AU$300 discount to clear out stock means the Supreme is cheaper than ever, available now for just AU$499. That's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results